标题
Chemotherapy-Resistant Metastatic Breast Cancer
作者
关键词
-
出版物
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 13, Issue 2, Pages 263-275
出版商
Springer Nature
发表日期
2012-04-15
DOI
10.1007/s11864-012-0184-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Vinflunine
- (2011) Luis Miguel Anton Aparicio et al. ANTI-CANCER DRUGS
- Reappraising antiangiogenic therapy for breast cancer
- (2011) Robert S. Kerbel BREAST
- Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor–Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium
- (2011) Denise A. Yardley et al. Clinical Breast Cancer
- Ixabepilone: Clinical Role in Metastatic Breast Cancer
- (2011) Neelima Denduluri et al. Clinical Breast Cancer
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
- (2011) S. Modi et al. CLINICAL CANCER RESEARCH
- Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
- (2011) Phuong K. Morrow et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
- (2011) Todd W. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Bevacizumab Treatment for Advanced Breast Cancer
- (2011) R. H. Alvarez et al. ONCOLOGIST
- Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
- (2010) L. D. Cripe et al. BLOOD
- Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials
- (2010) A. Valachis et al. BREAST CANCER RESEARCH AND TREATMENT
- DNA repair signature is associated with anthracycline response in triple negative breast cancer patients
- (2010) A. A. Rodriguez et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
- (2010) Andres Forero-Torres et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
- (2010) B. Schoeberl et al. CANCER RESEARCH
- Pilot Trial of Preoperative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Postmenopausal Women With Newly Diagnosed Estrogen Receptor— or Progesterone Receptor—Positive Breast Cancer
- (2010) Andres Forero-Torres et al. Clinical Breast Cancer
- HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
- (2010) M. R. Campbell et al. CLINICAL CANCER RESEARCH
- WhitherHER2-Related Therapeutics?
- (2010) Pradip De et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2010) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Breast Cancer Stem Cells
- (2010) Suling Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Phase 2 Study of Single-Agent IV Vinflunine as Third-Line Treatment of Metastatic Breast Cancer After Failure of Anthracycline-/Taxane-Based Chemotherapy
- (2009) Pierre Fumoleau et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen
- (2009) Paul Ruff et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
- (2009) Emmanuelle Charafe-Jauffret et al. CANCER RESEARCH
- Eribulin: Rediscovering Tubulin as an Anticancer Target
- (2009) A. Jimeno CLINICAL CANCER RESEARCH
- Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer
- (2009) Philippe Bedard et al. CURRENT CANCER DRUG TARGETS
- Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
- (2009) Sandra E. Ghayad et al. INTERNATIONAL JOURNAL OF CANCER
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Is resistance useless? Multidrug resistance and collateral sensitivity
- (2009) Matthew D. Hall et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling
- (2009) Hasan Korkaya et al. PLOS BIOLOGY
- Linking the Cellular Functions of BRCA Genes to Cancer Pathogenesis and Treatment
- (2008) Ashok R. Venkitaraman Annual Review of Pathology-Mechanisms of Disease
- TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype
- (2008) Monzur Rahman et al. BREAST CANCER RESEARCH AND TREATMENT
- Preclinical efficacy spectrum and pharmacokinetics of ixabepilone
- (2008) Francis Y. F. Lee et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
- (2008) S. T. Lee-Hoeflich et al. CANCER RESEARCH
- The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target
- (2008) M. Barginear et al. CURRENT CANCER DRUG TARGETS
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
- (2008) Grazia Arpino et al. ENDOCRINE REVIEWS
- Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
- (2008) Avi Ashkenazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Basal-Like Breast Cancer: A Critical Review
- (2008) Emad A. Rakha et al. JOURNAL OF CLINICAL ONCOLOGY
- Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
- (2008) Pascal Sève et al. LANCET ONCOLOGY
- HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
- (2008) H Korkaya et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started